YOYolanda Ortiz-Castro

Yolanda Ortiz-Castro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yolanda Ortiz-Castro has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early pregnancy protein multiplex screening reflects circulating and urinary divergences associated with the development of preeclampsia

    by Margarita L Martinez-Fierro, Claudia Castruita-De La Rosa, Idalia Garza-Veloz, Rosa M Cardiel-Hernandez, Marcela A Espinoza-Juarez, Ivan Delgado-Enciso, Maria E Castañeda-Lopez, Edith Cardenas-Vargas, Fabiola Trejo-Vázquez, Elma I Sotelo-Ham, et al.

    Background: Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to improve the prognosis of patients with preeclampsia. Objective: To evaluate the preeclampsia predictive value of 34 angiogenic-related proteins. Methods: We performed a nested cohort case-control study of pregnant women. The profile of the 34 proteins was evaluated at 12, 16, and 20 gestational weeks (GWs), using urine/plasma from 16 women who developed preeclampsia and 20 normotensive pregnant controls by Bio-Plex ProTM Human Cancer Biomarker Panels 1 and 2. Results: The urine concentration of soluble epidermal growth factor receptor (sEGFR), hepatocyte growth factor (HGF), angiopoietin-2 (ANG-2), endoglin (ENG), soluble fas ligand (sFASL), interleukin 6 (IL-6), placental growth factor (PLGF), and vascular endothelial growth factor A (VEGF-A) at 12 GW, prolactin (PRL), ANG-2, transforming growth factor alpha (TGF-α), and VEGF-A at 16 GW, and soluble IL-6 receptor alpha (sIL-6Rα), ANG-2 and sFASL at 20 GW, were different between groups (p < 0.05). The concentration cut-off values calculated in this study for the mentioned proteins, predicted an increased risk to developing preeclampsia in a range of 3.8–29.8 times in the study population. Conclusion: The proteins sEGFR, HGF, ANG-2, sFASL, IL-6, PLGF, VEGF-A, PRL, TGF-α FGF-b, sHER2/Neu sIL-6Rα, ENG, uPA, and insulin-like growth factor binding protein 1 (IGFBP-1), were predictive of the development of preeclampsia and their use as markers for this disease should be considered.


  • Maternal distress and the development of hypertensive disorders of pregnancy

    by Idalia Garza-Veloz, Claudia Castruita-De la Rosa, Yolanda Ortiz-Castro, Virginia Flores-Morales, Maria E. Castañeda-Lopez, Edith Cardenas-Vargas, Gloria P. Hernandez-Delgadillo, Vicente Ortega-Cisneros, Martha Luevano, Iram P. Rodriguez-Sanchez, et al.

    Despite the implementation of programmes to improve maternal health, maternal and foetal mortality rates still remain high. The presence of maternal distress and its association with the development of pregnancy hypertensive disorders is not well established. The aim of this study was to evaluate the association between maternal distress and the development of hypertensive disorders in pregnancy in a prospective cohort of 321 Mexican women. Symptoms of maternal distressing were evaluated at week 20th of gestation using the General Health Questionnaire. The presence of acute somatic symptoms, social dysfunction, anxiety and insomnia increased the odds of developing a pregnancy hypertensive disorder by 5.1–26.4 times in study population (p values < .05). Our results support the participation of maternal distress in the development of hypertensive disorders of pregnancy. The implementation of effective programmes prioritising risk factors during pregnancy including the presence of maternal distressing factors is recommended.